CytoDyn Announces New Data Suggesting Novel Mechanism Of Action Of Leronlimab In Solid Tumors
CytoDyn Inc. announced new data indicating a novel mechanism of action for leronlimab in treating solid tumors, particularly metastatic Triple-Negative Breast Cancer (mTNBC). The analysis revealed that 88% of patients receiving a weekly dose of 525 mg or higher showed increased expression of the immune checkpoint inhibitor PD-L1 on circulating tumor cells. This increase may enhance the tumors' response to immunotherapy. CEO Jacob Lalezari emphasized the importance of confirming these findings and mentioned amendments to their colorectal cancer trial to collect PD-L1 data.
CytoDyn Inc. (CYDY.OB), a biotechnology company, Tuesday announced new data suggesting a novel mechanism of action of leronlimab for the treatment of solid tumors.
CytoDyn analyzed data from its prior studies of patients with metastatic Triple-Negative Breast Cancer (mTNBC) and found that leronlimab treatment correlated with increased expression of an immune cell protein or checkpoint inhibitor known as programmed death-ligand 1 (PD-L1) on patients circulating tumor cells (CTCs).
Results from the analysis indicated that 88% of patients who received a weekly dose of 525 mg or higher experienced a significant increase in PD-L1 expression on their CTCs over a 30-to-90-day period after starting leronlimab. Increasing expression of PD-L1 can be likened to turning cold tumors hot, making them more likely to respond to immunotherapy.
"Leronlimabs ability to induce an inflamed or hot tumor environment, that could then be treated with ICIs, would be a game changer in solid tumor oncology. Prospectively confirming these findings in patients with TNBC is a top priority. We have also amended our current colorectal cancer trial to ensure the prospective collection of PD-L1 data in a second type of solid tumor," said Jacob Lalezari, CEO of CytoDyn.
For comments and feedback contact: editorial@rttnews.com
Business News
